Incorporating Pharmakon: HIV, Medicine, and Body Shape Change

Body & Society

Volumn 10, Issue 4, 2004, Pages 45-67

  Persson, Asha ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 23644443351     PISSN: 1357034X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1357034X04047855     Document Type: Article

References (74)

1. Appadurai, A. (1986) ‘Commodities and the Politics ofValue’, in A. Appadurai (ed.) The Social Life of Things, pp. 3-63. Cambridge: Cambridge University Press.
2. Ariss, R. (1997) Against Death: The Practice of Living with AIDS. Amsterdam: Gordon and Breach.
3. Bass, E. (2001) ‘Drug Toxicities Multiply and the MysteryGrows’, American Foundation for AIDS Research, http://ww2.aegis.org/pubs/amfar/2001/am010303.html
4. Broadhead, R.S. and N.J. Facchinetti (1985) ‘Drug Iatrogenesis and Clinical Pharmacy: The Mutual Fate of aSocial Problem and a Professional Movement’, Social Problems 32(5): 425-436.
5. Carpenter, C.J., M.A. Fischl, S.M. Hammer, M.S. Hirsch, D.M. Jacobsen, D.A. Katzenstein, J.S. Montaner, D.D. Richman, M.S. Saag, R.T. Schooley, M.A. Thompson, S. Vella, P.G. Yeni and P.A. Volberdinger (1997) ‘Antiretroviral Therapy for HIV Infection in 1997: UpdatedRecommendations of the International AIDS Society USA Panel’, Journal of the American Medical Association 276(2): 146-154.
6. Carr, A. (2003) ‘HIV Lipodystrophy: Risk Factors, Pathogenesis, Diagnosis and Management’, AIDS 17 (Suppl 1): S141-S148.
7. Carr, A. and D. Cooper (2000) ‘Adverse Effects of Antiretroviral Therapy’, The Lancet 356(9239): 1423-1430.
8. Carr, A., S. Emery, M. Law, R. Puls, J.D. Lundgren and W.G. Powderly (2003) ‘An Objective Case Definition of Lipodystrophy in HIV-infectedAdults: A Case-control Study’, The Lancet 361 (9359): 726-735.
9. Carr, A., K. Samaras, S. Burton, M. Law, J. Freund, D.J. Chisholm and D.A. Cooper (1998) ‘A Syndrome of Peripheral Lipodystrophy, Hyperlipidaemia andInsulin Resistance in Patients Receiving HIV Protease Inhibitors’, AIDS 12(7): F51-F58
10. Carr, A., K. Samaras, A. Thorisdottir, G.R. Kaufmann, D.J. Chisholm and D.A. Cooper (1999) ‘Diagnosis, Prediction, and Natural Course of HIV-1Protease-inhibitor-associated Lipodystrophy, Hyper-lipidaemia and DiabetesMellitus: A Cohort Study’, The Lancet 353(9170): 2093-2099.
11. Carter, V.M., J.F. Hoy, M. Bailey, P.G. Colman, I. Nyulasi and A.M. Mijch (2001) ‘The Prevalence of Lipodystrophy in an Ambulant HIV-infectedPopulation: It all Depends on the Definition’, HIV Medicine 2(3): 174-180.
12. Cohen, D., M. McCubbin, J. Collin and G. Pérodeau (2001) ‘Medications as Social Phenomena’, Health: An Interdisciplinary Journal for the Social Study ofHealth, Illness and Medicine 5(4): 441-469.
13. Collins, E., C. Wagner and S. Walmsley (2000) ‘Psychosocial Impact of the Lipodystrophy Syndrome in HIV Infection’, The AIDS Reader September: 546-550.
14. Crawford, R. (1994) ‘The Boundaries of the Self and the Unhealthy Other: Reflectionson Health, Culture and AIDS’, Social Science and Medicine 38(10): 1347-1365.
15. Davis, P. (1996) ‘Introduction: Medicines in a PostmodernWorld’, in P. Davis (ed.) Contested Ground: Public Purpose and Private Interest in theRegulation of Prescription Drugs, pp. 3-8. New York and Oxford: Oxford University Press.
16. Day, M. (2000) ‘No More Cocktails’, New Scientist 168(2269): 7-9.
17. Delaney, M. (2002) ‘Accelerated Approval: Where Are We Now?’, RITA: Research Initiative/Treatment Action! 8(1): 18-22. Houston, TX: Centre for AIDS.
18. Deleuze, G. and F. Guattari (1987) A Thousand Plateaus. Minneapolis: University of Minnesota Press.
19. Derrida, J. (2000[1981]) ‘Plato'sPharmacy’, in Dissemination, pp.61-171. London: The Athlone Press.
20. Desjarlais, R.R. (1992) Body and Emotion: The Aesthetic of Illness and Healingin the Nepal Himalayas. Philadelphia: University of Pennsylvania Press.
21. Dore, G., A. Grulich, M. Kidd, J. Hoy, R. McCoy, A. Mijch and S. Strasser (eds) (2001) HIV/Viral Hepatitis: A Guide to PrimaryCare. Sydney: Australasian Society for HIV Medicine (ASHM).
22. Ellard, J. (2002) ‘Negotiating Sex, Intimacy and Risk in Sero-discordant Regular Relationships’. Paper presented at Sero-discordant Relationships Forum, NSW Department of Health, Sydney, September.
23. Etkin, N.L. (1992) ‘'Side Effects': Cultural Constructions andReinterpretations of Western Pharmaceuticals’, Medical Anthropology Quarterly 6(2): 99-113.
24. Fee, E. and D. Fox (1992) AIDS: The Making of a Chronic Disease. Berkeley: University of California Press.
25. Foucault, M. (1975[1963]) Birth of the Clinic: An Archaeology of MedicalPerception. New York: Vintage.
26. Frank, A.W. (1995) The Wounded Storyteller: Body, Illness andEthics. Chicago, IL and London: University of Chicago Press.
27. Gilman, S. (1988) Disease and Representation: Images of Illness fromMadness to AIDS. Ithaca, NY and London: Cornell University Press.
28. Gilman, S. (1995) Health and Illness: Images of Difference. London: Reaktion Books.
29. Grosz, E. (1994) Volatile Bodies: Towards a Corporeal Feminism. Sydney: Allen and Unwin.
30. Gulick, R., J. Mellors, D. Havlir et al. (1998) ‘Simultaneous vs Sequential Initiation of Therapy with Indinavir,Zidovudine, and Lamivudine for HIV-1 Infection: 100-week Follow Up’, Journal of the American Medical Association 280(1): 35-41.
31. Haraway, D. (1989) ‘The Biopolitics of Postmodern Bodies: Determinations of Self inImmune System Discourse’, Differences 1(1): 3-43.
32. Helman, C. (1990) Culture, Health and Illness. London and Boston, MA: Wright.
33. Ho, D.D. (1995) ‘Time to Hit HIV, Early and Hard’, The New England Journal of Medicine 333(7): 450-451.
34. Hurley, M. (2001) ‘Rethinking the Clinic: Doctors, People Living with HIV and AIDSand Cultures of Care'. Paper presented at 13th Annual Conference of AustralasianSociety for HIV Medicine, Melbourne.
35. Illich, I. (1976) Medical Nemesis: The Expropriation of Health. New York: Pantheon.
36. Kitzinger, J. (1995) ‘The Face of AIDS’, in Markova, I. and Farr, R.M. (eds) Representations of Health, Illness and Handicap, pp.49-66. Singapore: Harwood Academic Publishers.
37. Kleinman, A. (1988) The Illness Narratives: Suffering, Healing, and theHuman Condition. New York: Basic Books.
38. Kleinman, A. (1995) Writing at the Margin: Discourse between Anthropologyand Medicine. Berkeley: University of California Press.
39. Lauritsen, J. (1990) Poison by Prescription: The AZT Story. New York: Asklepios.
40. Leder, D. (1990) The Absent Body. Chicago, IL: University of Chicago Press.
41. Machon, K. (1999) ‘Cause and Effect’, HIV Herald 8(5): 3-4.
42. Machon, K. and C. Batrouney (1999) ‘An A-Z of Side Effects’, HIV Herald 8(5): 9-18.
43. Martin, E. (1992) ‘The End of the Body?’, American Ethnologist 19(1): 121-140.
44. Martin, E. (1994) Flexible Bodies: The Role of Immunity in AmericanCulture from the Days of Polio to the Age of AIDS. Boston, MA: Beacon Press.
45. Mascolini, M. (1999) ‘Crossing the Waters to the Post-HAART Era’, Journal of the International Association of Physicians in AIDS Care December: 13-51.
46. Merleau-Ponty, M. (1962) Phenomenology of Perception. London: Routledge and Kegan Paul.
47. Miller, J., A. Carr, S. Emery, M. Law, S. Mallal, D. Baker, D. Smith, J. Kaldor and D.A. Cooper (2003) ‘HIV Lipodystrophy: Prevalence, Severity and Correlates of Riskin Australia’, HIV Medicine 4(3): 293-301.
48. Montagne, M. (1996) ‘The Pharmakon Phenomenon: CulturalConceptions of Drugs and Drug Use’, in P. Davis (ed.) Contested Ground: Public Purpose and Private Interest in theRegulation of Prescription Drugs, pp. 11-25. New York and Oxford: Oxford University Press.
49. Nass, H. (2003) ‘Metabolic Complications: A Look at the IASGuidelines’, AIDS Community Research Initiative of America (ACRIA), http://ww2.aegis.org/pubs/cria/2003/CR030406.html
50. Nichter, M. and N. Vuckovic (1994) ‘Agenda for an Anthropology of Pharmaceutical Practice’, Social Science and Medicine 39(11): 1509-1525.
51. Obeyesekere, G. (1980) Rationality, Theory, and Experimentation in AyurvedicMedicine. Tokyo: The United Nations University.
52. Ohnuki-Tierney, E. (1981) Illness and Healing Among the Sakhalin Ainu: ASymbolic Interpretation. Cambridge: Cambridge University Press.
53. Persson, A., K. Race and E. Wakeford (2003) ‘HIV Health in Context: Negotiating Medical Technology and Lived Experience’, Health: An Interdisciplinary Journal for the Social Study ofHealth, Illness and Medicine 7(4): 397-415.
54. Power, R., H.L. Tate, S.M. McGill and C. Taylor (2003) ‘A Qualitative Study of the Psychosocial Implications ofLipodystrophy Syndrome on HIV Positive Individuals’, Sexually Transmitted Infections 79(2): 137-141.
55. Race, K. (2001a) ‘The Undetectable Crisis: Changing Technologies of Risk’, Sexualities 4(2): 167-189.
56. Race, K. (2001b) ‘Incorporating Clinical Authority: A New Test for People with HIV’, in N. Watson and S. Cunningham-Burley (eds) Reframing the Body, pp. 81-95. Hampshire and New York: Palgrave.
57. Rofes, E. (1998) Dry Bones Breathe: Gay Men Creating Post-AIDSIdentities and Cultures. New York and London: Harrington Park Press.
58. Rosello, M. (1998) ‘Pictures of a Virus: Ideological Choices and the Representationof HIV’, French Cultural Studies 9(27): 337-349.
59. Siegel, K. and H-M. Lekas (2002) ‘AIDS as a Chronic Illness: Psychosocial Implications’, AIDS 16 (suppl 4): S69-S76.
60. Silverman, M. and P.R. Lee (1974) Pills, Profits, and Politics. Berkeley: University of California.
61. Sontag, S. (1990) AIDS and its Metaphors. New York: Doubleday.
62. Stewart, G. (ed.) (1997) Managing HIV. Sydney: Australasian Medical Publishing Company Limited.
63. Taylor, C.C. (1988) ‘The Concept of Flow in Rwandan Popular Medicine’, Social Science and Medicine 27(12): 1343-1348.
64. Toombs, S.K. (1988) ‘Illness and the Paradigm of Lived Body’, Theoretical Medicine 9(2): 201-226.
65. Treichler, P. (1991) ‘AIDS, Homophobia, and BiomedicalDiscourse: An Epidemic of Signification’, in D. Crimp (ed.) AIDS: Cultural Analysis, Cultural Activism, pp.31-70. Cambridge, MA and London: MIT Press.
66. Van der Geest, S. and S.R. Whyte (eds) (1988) The Context of Medicines in DevelopingCountries. Dordrecht: Kluwer Academic Publishers.
67. Van der Geest, S. and S.R. Whyte (1989) ‘The Charm of Medicines: Metaphors and Metonyms’, Medical Anthropology Quarterly 3(4): 345-367.
68. Van der Geest, S., S.R. Whyte and A. Hardon (1996) ‘The Anthropology of Pharmaceuticals: A Biographical Approach’, Annual Review of Anthropology 25(1): 153-178.
69. Voelker, R. (1996) ‘Can Researchers Use New Drugs to Push HIV Envelope to Extinction?’, Journal of the American Medical Association 276(6): 435-437.
70. Volberding, P.A. and S. Deeks (1998) ‘Antiretroviral Therapy for HIV Infection: Promises and Problems’, Journal of the American Medical Association 279(17): 1343-1344.
71. Waldby, C. (1999) ‘IatroGenesis: The Visible Human Project and the Reproduction of Life’, Australian Feminist Studies 14(29): 77-90.
72. Willems, D. (1998) ‘Inhaling Drugs and Making Worlds: AProliferation of Lungs and Asthmas’, in M. Berg and A. Mol (eds) Differences in Medicine: Unravelling Practices, Techniques, andBodies, pp. 105-118. Durham, NC and London: Duke University Press.
73. Williams, S. and G. Bendelow (2000) ‘'Recalcitrant Bodies'? Children, Cancer andthe Transgressions of Corporeal Boundaries’, Health: An Interdisciplinary Journal for the Social Study ofHealth, Illness and Medicine 4(1): 51-71.
74. Williams, S. and M. Calnan (1996) ‘The’Limits' of Medicalization? ModernMedicine and the Lay Populace in’Late' Modernity’, Social Science and Medicine 42(12): 1609-1620.